Follicular Lymphoma

Rituximab added to standard anthracycline-based chemotherapy demonstrated significant improvements in progression-free survival as well as overall survival as treatment of patients with follicular lymphoma, according to 35-year follow-up results of patients treated through the Nebraska Lymphoma Study Group.

Connie L. Batlevi, MD, PhD, discusses the efficacy of tazemetostat in patients with follicular lymphoma and an EZH2 mutation.

In an interview with Targeted Oncology, John M. Burke, MD, discussed the current treatment paradigm for patients with follicular lymphoma and reviewed the factors he considers when making treatment decisions for this population.

A phase clinical trial has demonstrated that administering a mosunetuzumab fixed-duration leads to high, durable, and consistent responses in patients with follicular lymphoma across multiple subgroups. Data from the study were presented during the virtual 2020 American Society of Hematology Annual Meeting.

A new retrospective analysis has suggested that the R-CHOP chemotherapy regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone leads to superior outcomes compared to rituximab plus bendamustine in patients with grade 3A follicular lymphoma.

A general framework can be utilized to guide treatment decision in patients with follicular lymphoma, according to John P. Leonard, MD. During a presentation for the 38th Annual Chemotherapy Foundation Symposium, Leonard also explained that bulk of disease, comorbidities, and toxicity, among others are all factors that impact treatment decisions.

The primary end point of prolonged progression-free survival in the phase 3 CHRONOS-3 study was met with copanlisib in combination with rituximab as treatment of patients with indolent non-Hodgkin lymphoma.

Tazemetostat as a single agent demonstrated clinically meaningful durable responses as treatment of patients with heavily pretreated relapsed/refractory follicular lymphoma.

The FDA has accepted a supplemental Biologics License Application for axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma after 2 or more prior lines of systemic therapy.

The question of whether patients with asymptomatic advanced-stage follicular lymphoma should undergo watch-and-wait observation or start treatment immediately was addressed at the 2020 Debates and Didactics in Hematology and Oncology during a debate between Jean Louise Koff, MD, MS, and James O. Armitage, MD.

Lenalidomide in combination with rituximab (Rituxan, R2) induction has the ability to achieve high rates of complete molecular response (CMR), similar to rituximab plus chemotherapy, when used as frontline therapy in patients with follicular lymphoma (FL), according to results from the phase 3 RELEVANCE trial (NCT01650701).

Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.

In an interview with Targeted Oncology, John P. Leonard, MD, discussed the results of the phase 2 study of tazemetostat, the drug approval for relapsed/refractory follicular lymphoma, and the role of tazemetostat in the community setting.

"The durable responses observed with this drug are notable in the context of the safety profile and route of oral, at-home administration, and will offer an important new option for physicians as we care for patients with relapsed/refractory follicular lymphoma."

“The completion of this New Drug Application submission marks an important milestone in bringing us 1 step closer to providing umbralisib as a potential treatment option for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma."

Follicular Lymphoma